Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD001 in PSMA-expressing metastatic castration-resistant prostate cancer
2025-523273-41-00Phase 2Authorised
- Sponsor
- TOAD Oncology
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of TOAD-1 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by TOAD Oncology. Primary endpoints: Incidence and severity of dose-limiting toxicities during Cycle 1 (dose escalation only), Incidence, severity, and relationship of adverse events and serious adverse events and 2 more. Planned start Jan 2026; status: authorised.
02
Drugs
TOAD-1
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2025-523273-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523273-41-00.